Diagnosis, monitoring, or prognosis of diabetes or pre-diabetes.
Evaluating GAG-bound Rbp, Agp, FN, and CFH proteins offers a more accurate and efficient approach to diagnose and monitor diabetes and prediabetes, addressing the limitations of existing methods.
BR112025019032A2Pending Publication Date: 2026-07-07SERVIZO GALEGO DE SAUDE +2
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- BR112025019032
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-09
- Filing Date
- 2024-03-11
- Publication Date
- 2026-07-07
Smart Images
Figure 00000000_0000_ABST
Abstract
The present invention refers to an in vitro method for the diagnosis, monitoring or prognosis of IGT / diabetes or prediabetes; or for screening or selecting patient candidates to be subjected to OGTT, which comprises assessing the amount of a protein, selected from the group consisting of: Retinol-Binding Protein 4 (Rbp), Alpha-l-acid glycoprotein (Agp), fibronectin (FN), and / or Complement factor H (CFH) which is bound to glycosaminoglycans (GAGs).
Need to check novelty before this filing date? Find Prior Art